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VIDEO CASE SERIESWritt
wwwEUS-guided portal pressure gradient measurement with a simple
novel device: a human pilot studyen tran
.VideoJason B. Samarasena, MD, Jason Y. Huang, FRACP, Takeshi Tsujino, MD, PhD, Daniel Thieu, BSc,
Allen Yu, BSc, Ke-Qin Hu, MD, John Lee, MD, Kenneth J. Chang, MDBackground and Aims: Portal hypertension is a serious adverse event of liver cirrhosis. Recently, we devel-
oped a simple novel technique for EUS-guided portal pressure gradient (PPG) measurement (PPGM). Our an-
imal studies showed excellent correlation between EUS-PPGM and interventional radiology-acquired PPGM. In
this video we demonstrate the results of the first human pilot study of EUS-PPGM in patients with liver
disease.
Methods: EUS-PPGM was performed by experienced endosonographers using a linear echoendoscope, a
25-gauge FNA needle, and a novel compact manometer. The portal vein and hepatic vein (or inferior
vena cava) were targeted by use of a transgastric or transduodenal approach. Feasibility was defined as
successful PPGM in each patient. Safety was based on adverse events captured in a postprocedural interview.
Results: Twenty-eight patients underwent EUS-PPGM with 100% technical success and no adverse events.
PPG ranged from 1.5 to 19 mm Hg and had excellent correlation with clinical parameters of portal hyperten-
sion, including the presence of varices (P Z .0002), PH gastropathy (P Z .007), and thrombocytopenia
(P Z .036).
Conclusion: This novel technique of EUS-PPGM using a 25-gauge needle and compact manometer is feasible
and appears safe. Given the availability of EUS and the simplicity of the manometry setup, EUS-guided PPG
may represent a promising breakthrough for procuring indispensable information in the management of patients
with liver disease. (Gastrointest Endosc 2018;3:361-3.)Portal hypertension (PH) is a severe adverse event of
liver cirrhosis. Clinical manifestations may include the
formation of varices with associated GI bleeding, ascites,
encephalopathy, or hepatorenal syndrome.1,2 Therefore,
the diagnosis and quantification of PH by measuring portal
pressure hold tremendous therapeutic and prognostic
implications.2-4
The portal pressure gradient (PPG) is the difference be-
tween the portal vein (PV) pressure and the pressure within
the hepatic vein (HV) (or inferior vena cava). It reflects the
hepatic perfusion pressure. In patients with cirrhosis, portal
pressure increases because of increased intrahepatic
vascular resistance and increased portal blood flow.2
PPG is derived by subtracting theHV pressure from the PV
pressure. These pressures ideally should be obtained
through direct venous puncture. Currently, the PV pressure
is not routinely measured. Instead, it is indirectly estimated
by use of the wedged HV pressure (WHVP), which approxi-script of the video audio is available online at www.VideoGIE.org.
GIE.orgmates PV pressure in the cirrhotic liver. Thus, only the HV
pressure is a true direct measurement. This gradient is
termed the HV pressure gradient (HVPG), and it accurately
reflects the degree of PH in all forms of sinusoidal and post-
sinusoidal causes of PH.1,5,6
We have already described EUS-guided PPG measure-
ment using a 25-gauge needle and a novel compact manom-
eter in an animal model.7 Our method demonstrated
excellent accuracy and a strong correlation with pressure
values obtained by the criterion standard of transjugular
wedged and free HV pressure measurements by
interventional radiology. Here, we present the first pilot
study in humans demonstrating safe and accurate direct
PPG measurements without the need for ionizing
radiation, transhepatic catheter placement, or surgery
(Video 1, available online at www.VideoGIE.org).
EUS-PPG was performed at a single tertiary academic
center by experienced endosonographers. All cases wereVolume 3, No. 11 : 2018 VIDEOGIE 361
Figure 1. Compact manometer.
Video Case Series Samarasena et alperformed with the patients under monitored anesthesia
or general anesthesia and placed in the supine position.
Patients between the ages of 18 and 75 with a history of
liver disease or suspected cirrhosis were considered for
PPG measurement.
The apparatus for PPG measurement included a linear
echoendoscope (GF-UC140P-AL5; Olympus, Tokyo, Japan),
a 25-gauge FNA needle (Cook Medical, Winston-Salem,
NC, USA), and a compact manometer (Fig. 1) with non-
compressible tubing (Cook Medical, Bloomington, Ind,
USA). The compact manometer has a digital readout and
measures 2 cm  3 cm  2 cm, and it is currently not avail-
able commercially.
Before PPG measurement, an endoscopic evaluation
was performed to evaluate for markers of PH such as vari-
ces and portal hypertensive gastropathy. The endoscopists
were not blinded to clinical information before the PPG
measurements. For PPG measurement, the patients were
placed in a supine position, and the manometer was ze-
roed at the midaxillary line before echoendoscope inser-
tion. Measurements were conducted in the PV (Fig. 2)
and HV (Fig. 3) where possible. If the HV was
inaccessible because of anatomic limitations, the inferior
vena cava was targeted. PV manometry was performed
through a transgastric or a transduodenal (1 patient),
transhepatic approach, and only the intrahepatic portion
near the PV bifurcation was accessed. A small amount (1
mL) of heparinized saline solution (100 IU/mL) was
flushed through the primed FNA needle (no stylet)
before each EUS reading. After 30 to 60 seconds of
pressure stabilization, the reading was recorded. Three
separate readings per vessel were performed, and a
mean pressure was calculated. On withdrawal of the
needle, just before leaving the liver capsule, color
Doppler was used to ensure absence of flow in the
needle track. Intraprocedural prophylactic antibiotics
were given.
A total of 28 patients underwent portal pressure
manometry in this retrospective study, and pressures
were successfully achieved in all 28 patients. Eighteen pa-
tients were male; conditions and indications included viral
hepatitis (15 patients), alcohol use (6), increased liver
function test results (5), and nonalcoholic fatty liver dis-
ease (2). There were 16 patients with a platelet count
less than 150, and 4 patients had International Normalized
Ratios >1.2.
PPG values ranged from 1.5 to 19 mm Hg (mean,
8.2 mm Hg). Fifteen of 28 patients (57.1%) had evidence
of PH based on PPG, of whom 10 of 15 (66.7%) had clini-
cally significant portal hypertension (CSPH). Eleven of 28
study participants had endoscopic evidence of either
esophageal or gastric varices, with all 11 (100%) having
PH and 10 (90.9%) patients having CSPH based on EUS-
PPG measurement.362 VIDEOGIE Volume 3, No. 11 : 2018No intraprocedural or postprocedural adverse events
such as bleeding, perforation, or pain were seen in any
patient. There were no infectious adverse events. There
was excellent association between PPG and clinical
parameters.8
Limitations to the study include its retrospective na-
ture. There was also no criterion standard for correlation
such as interventional radiology–acquired pressure mea-
surements. This study demonstrates that EUS-guided por-
tal pressure measurement by use of a 25-gauge needle
and a novel compact manometer is feasible and appears
safe in humans. There were no technical failures with
PPG manometry, and there were no adverse events in
any patient.DISCLOSURE
Dr Samarasensa and Dr Lee are the recipients of
educational grants from Cook Medical. Dr Chang is a
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Figure 3. A, EUS image of transgastric transhepatic needle puncture into the hepatic vein with a 25-gauge FNA needle. B, Representation of EUS-guided
transgastric hepatic vein puncture.
Figure 2. A, EUS image of transgastric transhepatic needle puncture into the portal vein with a 25-gauge FNA needle. B, Representation of EUS-guided
transgastric portal vein puncture.
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